Immunovant Is Maintained at Overweight by Wells Fargo

Dow JonesDec 19 22:58 · Ratings

Immunovant Analyst Ratings

BenzingaDec 19 22:47 · Ratings

FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline With Promising Results and FDA Green Light for Pivotal Trial

Yahoo FinanceDec 11 19:25

Graves' Disease Pipeline Drug Research Report 2024 Featuring Viridian Therapeutics, Immunovant Sciences, Apitope International, Sling Therapeutics, and Novartis

Yahoo FinanceDec 2 18:23

Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025

Seeking AlphaNov 26 04:10

Have Immunovant Insiders Been Selling Stock?

Simply Wall StNov 25 18:13